Supplementary Table 4 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity

NIAID Data Ecosystem2026-05-02 收录

数据链接：

https://figshare.com/articles/dataset/Supplementary_Table_4_from_Multifunctional_Bispecific_Nanovesicles_Targeting_SLAMF7_Trigger_Potent_Antitumor_Immunity/26422565 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Table 4

创建时间：

2024-08-01

Supplementary Material for: Exploring the expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot Study

癌症免疫治疗

免疫荧光技术

Introduction: Generating high levels of immunosuppressive adenosine in the tumor microenvironment contributes to cancer immune evasion. CD39 and CD73 hydrolyze adenosine triphosphate into adenosine; t

DataCite Commons2023-11-03 更新80

Additional file 12 of Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy

癌症免疫治疗

生物标志物

Additional file 12. The identified biomarkers and their functions. The identified biomarkers from the decision tree and their functions are shown in this file

DataCite Commons2020-08-25 更新30

Effects of Bisphosphonate Ligands and PEGylation on Targeted Delivery of Gold Nanoparticles for Contrast-Enhanced Radiographic Detection of Breast Microcalcifications

靶向纳米药物

乳腺微钙化影像检测

Data files for each figure and table in the paper.

NIAID Data Ecosystem30

DataSheet_1_T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.pdf

癌症免疫治疗

疫苗免疫原性

The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer vaccines across a wide

NIAID Data Ecosystem30

RNA sequencing of the phase II PERFECT trial combining a PD-L1 inhibitor (atezolizumab) with neoadjuvant chemoradiotherapy in resectable esophageal adenocarcinoma patients.. RNA sequencing of the phase II PERFECT trial combining a PD-L1 inhibitor (atezolizumab) with neoadjuvant chemoradiotherapy in resectable esophageal adenocarcinoma patients.

癌症免疫治疗

RNA测序

We performed bulk RNA sequencing of tumor biopsies from patients before treatment, on-treatment and in case a poor response was suspected from the resection specimen. At baseline we found in respondin

NIAID Data Ecosystem30

Supplementary Table 4 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity

资源简介：

相关数据集